Royalty Pharma (RPRX) closed at $66.40 on Nov 3, 2026, down 0.2% on the day. The stock is up 17.2% over the past month, up 15.4% over three months, up 74.2% year to date and up 81.5% over the past year (since Nov 3, 2025). It trades 1.9% below its 52-week high of $67.71 and 87.9% above its 52-week low of $35.34. The close sits above its 50-day moving average ($60.48) and above its 200-day moving average ($53.24).
RPRX is scheduled to report earnings on Nov 4, 2026, before market open. Over its last 8 reports the stock moved an average of 2.0% on the first trading day after earnings, beating the options-implied move in 1 of 8.
Royalty Pharma is scheduled to report on Nov 4, 2026, before market open.
Over the last 8 reports, RPRX moved an average of 2.0% on the first trading day after earnings. The move beat the options-implied move in 1 of 8 reports.
Yes — the Nov 3, 2026 close of $66.40 is 24.7% above the 200-day average of $53.24.
RPRX closed 1.9% below its 52-week high of $67.71.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
